Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-finding study of induction cisplatin + docetaxel + escalating capecitabine followed by cetuximab plus radiotherapy in locally advanced inoperable head and neck squamous cell carcinoma
2010-018363-42Phase 2Active
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- Dec 2010
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine, cisplatin, docetaxel and cetuximab in head and neck squamous cell carcinoma (HNSCC), sponsored by Istituto Nazionale Tumori IRCCS Fondazione Pascale. Primary endpoints: Objective response, Toxicity and 1 more. Started Dec 2010; status: active.
02
Drugs
capecitabinecisplatindocetaxelcetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2010-018363-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018363-42.